Best Practice & Research Clinical Rheumatology
Volume 21, Issue 6 , Pages 1079-1092 , December 2007

The treatment of antiphospholipid syndrome: A harmonic contrast

  • Munther A. Khamashta, MD, FRCP, PhD

      Affiliations

    • Corresponding Author InformationCorresponding author. Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London SE1 7EH, UK. Tel.: +44 020 7620 2567; Fax: +44 020 7620 26 58.

References 

  1. Hughes GRV. Thrombosis, abortion, cerebral disease and the lupus anticoagulant. British Medical Journal. 1983;287:1088–1099
  2. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis & Rheumatism. 2002;46:1019–1027
  3. Sanna G, D'Cruz D, Cuadrado MJ. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheumatic Disease Clinics of North America. 2006;32:465–490
  4. Tektonidou MG, Ioannidis JPA, Boki KA, et al. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndome. Quarterly Journal of Medicine. 2000;93:523–530
  5. Lockshin MD, Druzin ML, Goei S, et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. The New England Journal of Medicine. 1985;313:152–156
  6. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Annals of Internal Medicine. 1992;117:303–308
  7. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid antibody syndrome. The New England Journal of Medicine. 1995;332:993–997
  8. Hyers TM, Agnelli G, Hull R, et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001;119:176S–193S
  9. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest. 2001;119:22S–38S
  10. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome. The New England Journal of Medicine. 2003;349:1133–1138
  11. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). Journal of Thrombosis and Haemostasis. 2005;3:848–853
  12. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. The Journal of the American Medical Association. 2006;295:1050–1057
  13. Lima F, Khamashta MA, Buchanan NMM, et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clinical and Experimental Rheumatology. 1996;14:131–136
  14. Branch DW, Silver RM, Blackwell JL, et al. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstetrics & Gynecology. 1992;80:614–620
  15. Granger KA, Farquharson RG. Obstetric outcome in antiphospholipid syndrome. Lupus. 1997;6:509–513
  16. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). British Medical Journal. 1997;314:253–257
  17. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstetrics & Gynecology. 2002;100:408–413
  18. Empson M, Lassere M, Craig J, et al. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane database of systematic reviews. 2005;18(2):CD002859
  19. Urowitz MB, Gladman DD. Contributions of observational cohort studies in systemic lupus erythematosus: the University of Toronto lupus clinic experience. Rheumatic Disease Clinics of North America. 2005;31:211–221
  20. Levine SR, Brey RL, Tilley BC, et al. APASS Investigators Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. The Journal of the American Medical Association. 2004;291:576–584
  21. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis & Rheumatism. 1999;42:1309–1311
  22. Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. The New England Journal of Medicine. 2001;345:1444–1451
  23. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis & Rheumatism (in press).
  24. Derksen RHWM, de Groot PG, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Annals of the Rheumatic Diseases. 1993;52:689–692
  25. Krnic-Barrie S, O'Connor CR, Looney SW, et al. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Archives of Internal Medicine. 1997;157:2101–2108
  26. Muñoz-Rodriguez FJ, Font J, Cervera R, et al. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Seminars in Arthritis and Rheumatism. 1999;29:182–190
  27. Ruiz-Irastorza G, Khamashta MA, Hunt BJ, et al. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target INR of 3.5. Archives of Internal Medicine. 2002;162:1164–1169
  28. Wittkowsky AK, Downing J, Blackburn J, Nutescu E. Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic. Thrombosis and Haemostasis. 2006;96:137–141
  29. Girón-González JA, García del Rio E, Rodriguez C, et al. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. The Journal of Rheumatology. 2004;31:1560–1567
  30. Ames PRJ, Ciampa A, Margaglione M, et al. Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation. A 8-year longitudinal comparison with mitral valve replacement and inherited thrombophilia. Thrombosis and Haemostasis. 2005;93:694–699
  31. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood. 1995;10:3685–3691
  32. Prandoni P, Simioni P, Girolami A. Antiphospholipid antibodies, recurrent thromboembolism and intensity of warfarin anticoagulation. Thrombosis and Haemostasis. 1996;75:859
  33. Rance A, Emmerich J, Fiessinger JN. Anticardiolipin antibodies and recurrent thromboembolism. Thrombosis and Haemostasis. 1997;77:221–222
  34. Schulman S, Svenungsson E, Granqvist S the Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. American Journal of Medicine. 1998;104:332–338
  35. Toloza SMA, Uribe AG, McGwin G, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis & Rheumatism. 2004;50:3947–3957
  36. Hansen KE, Kong DF, Moore KD, Ortel TL. Risk factors associated with thrombosis in patients with antiphospholipid antibodies. The Journal of Rheumatology. 2001;28:2018–2024
  37. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis. 2006;4:295–306
  38. Lackner KJ, Peetz D, von Landenberg P. Revision of the Sapporo criteria for the antiphospholipid syndrome – coming to grips with evidence and Thomas Bayes?. Thrombosis and Haemostasis. 2006;95:917–919
  39. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827–1832
  40. Turiel M, Sarzi-Puttini P, Peretti R, et al. Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study. Stroke. 2005;36:1490–1494
  41. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. American Journal of Medicine. 1996;100:530–536
  42. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. Journal of Thrombosis and Haemostasis. 2005;3:1231–1238
  43. Martinez-Berriotxoa A, Ruiz-Irastorza G, Egurbide MV, et al. Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Lupus. 2007;16:810–816
  44. Edwards MH, Pierangeli S, Liu X, et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation. 1997;96:4380–4384
  45. Espinola RG, Pierangeli SS, Gharavi AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thrombosis and Haemostasis. 2002;87:518–522
  46. Wallace DJ. Does hydroxychloroquine sulphate prevent clot formation in systemic lupus erythematosus?. Arthritis & Rheumatism. 1987;30:1435–1436
  47. Wallace DJ, Linker-Israeli M, Metzger AL, Stecher VJ. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus. 1993;2(Suppl 1):S13–S15
  48. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus. 1996;5(Suppl 1):S16–S22
  49. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scandinavian Journal of Rheumatology. 1996;25:191–193
  50. Erkan D, Yazici Y, Peterson MG, et al. A cross-section study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology. 2002;41:924–929
  51. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15:577–583
  52. Lopez-Pedrera Ch, Buendia P, Aguirre MA, et al. Antiphospholipid syndrome and tissue factor: a thrombotic couple. Lupus. 2006;15:161–166
  53. Ferrara DE, Liu X, Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis & Rheumatism. 2003;48:3272–3279
  54. Ferrara DE, Swerlick R, Casper K, et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. Journal of Thrombosis and Haemostasis. 2004;2:1558–1563
  55. Meroni PL, Raschi E, Testoni C, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis & Rheumatism. 2001;44:2870–2878
  56. Brey RL. New treatment option for the antiphospholipid antibody syndrome? More pleiotropic effects of the statin drugs. Journal of Thrombosis and Haemostasis. 2004;2:1556–1557
  57. Pierangeli SS, Girardi G, Vega-Ostertag M, et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis & Rheumatism. 2005;52:2120–2124
  58. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nature Medicine. 2004;10:1222–1226
  59. Lockshin MD, Drunzin MI, Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. American Journal of Obstetrics and Gynecology. 1989;160:439–443
  60. Silver RK, MacGregor SN, Sholl JS, et al. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. American Journal of Obstetrics and Gynecology. 1993;169:1411–1417
  61. Cowchock FS, Reece EA, Balaban D, et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin. American Journal of Obstetrics and Gynecology. 1992;166:1318–1323
  62. Triolo G, Ferrante A, Ciccia F, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis & Rheumatism. 2003;48:728–731
  63. Branch DW, Peaceman AM, Druzin M, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. American Journal of Obstetrics and Gynecology. 2000;182:122–127
  64. Petri M, Qazi U. Management of antiphospholipid syndrome in pregnancy. Rheumatic Disease Clinics of North America. 2006;32:591–607
  65. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. American Journal of Obstetrics and Gynecology. 1996;174:1584–1589
  66. Huong DLT, Wechsler B, Bletry O, et al. A study of 75 pregnancies in patients with antiphospholipid syndrome. The Journal of Rheumatology. 2001;28:2025–2030
  67. Carmona F, Font J, Azulay M, et al. Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis. American Journal of Reproductive Immunology. 2001;46:274–279
  68. Cowchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial. American Journal of Obstetrics and Gynecology. 1997;176:1099–1100
  69. Pattison NS, Chamley LW, Birdsall M, et al. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. American Journal of Obstetrics and Gynecology. 2000;183:1008–1012
  70. Noble LS, Kutteh WH, Lashey N, et al. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertility and Sterility. 2005;83:684–690
  71. Stephenson MD, Ballem PJ, Tsang P, et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. Journal of Obstetrics and Gynaecology Canada. 2004;26:729–734
  72. Bates S, Greer IA, Hirsh J, et al. Use of antithrombotic agents during pregnancy. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:627S–644S
  73. Tincani A, Branch W, Levy RA, et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus. 2003;12:524–529
  74. Ruiz-Irastorza G, Khamashta MA, Hughes GRV. Treatment of pregnancy loss in Hughes syndrome: a critical update. Autoimmunity Reviews. 2002;1:298–304
  75. Branch DW, Khamashta MA. Antiphospholipid syndrome: Obstetric diagnosis, management and controversies. Obstetrics & Gynecology. 2003;101:1333–1344
  76. Ruiz-Irastorza G, Khamashta MA. Management of thrombosis in antiphospholipid syndrome and systemic lupus erythematosus in pregnancy. Annals of the New York Academy of Sciences. 2005;1051:606–612
  77. Horlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Regional Anesthesia and Pain Medicine. 2003;28:172–197
  78. Wetzl RG. Anestesiological aspects of pregnancy in patients with rheumatic diseases. Lupus. 2004;13:699–702
  79. Cuadrado MJ, Mendonça LLF, Khamashta MA, et al. Maternal and fetal outcome in antiphospholipid syndrome pregnancies with a history of previous cerebral ischemia (abstract). Arthritis & Rheumatism. 1999;42:S265
  80. Hunt BJ, Khamashta MA, Lakasing L, et al. Thromboprophylaxis in antiphospholipid syndrome pregnancies with previous cerebral arterial thrombotic events: is warfarin preferable?. Thrombosis and Haemostasis. 1998;79:1060–1061
  81. Pauzner R, Dulitzki M, Lanevitz P, et al. Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy. Thrombosis and Haemostasis. 2001;86:1379–1384
  82. Ostensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis research & therapy. 2006;8:209;(Epub 2006 May 11)
  83. Bonnin M, Mercier FJ, Sitbob , et al. Severe pulmonary hypertension during pregnancy. Mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology. 2005;102:1133–1137
  84. Papageorghiou AT, Roberts N. Uterine artery Doppler screening for adverse pregnancy outcome. Current opinion in obstetrics & gynecology. 2005;17:584–590
  85. Kerslake S, Morton KE, Versi E, et al. Early doppler studies in lupus pregnancy. American Journal of Reproductive Immunology. 1992;28:172–175
  86. Le Thi Huong D, Wechsler B, Vauthier-Brouzes D, et al. The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome. Rheumatology (Oxford). 2006;45:332–338

PII: S1521-6942(07)00111-8

doi: 10.1016/j.berh.2007.10.003

Best Practice & Research Clinical Rheumatology
Volume 21, Issue 6 , Pages 1079-1092 , December 2007

Article Tools